Akcea Announces Appointment of New Chief Operating Officer
December 04, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company...
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
November 25, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
November 19, 2019 16:05 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
Akcea Therapeutics to Present at Upcoming Investor Conferences
November 13, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
Akcea Reports Financial Results and Highlights for Third Quarter 2019
November 05, 2019 16:05 ET
|
Akcea Therapeutics, Inc.
Reported Third Quarter 2019 Global Net Product Revenues of $12 Million WAYLIVRA® (volanesorsen) launched in the E.U. Entered into a worldwide licensing agreement with Pfizer, Inc. for...
Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
November 01, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today recognizes Familial Chylomicronemia...
Akcea Announces Appointment of New Chief Commercial Officer
October 23, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that the company has promoted Kyle Jenne...
Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
October 22, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, November...
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
October 07, 2019 06:50 ET
|
Akcea Therapeutics, Inc.; Pfizer Inc.
BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE),...
Akcea Announces CEO Transition and Elects Two New Board Members
September 23, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has...